Biography

Sigmund Hsu, MD, is fellowship trained and certified by the American Board of Psychiatry and Neurology, with extensive experience in the evaluation and treatment of neurological disorders in cancer patients. He specializes in primary brain tumors as well as brain and spinal cord metastases, cancer neurology and the treatment of chemotherapy neurotoxicity.

Dr. Hsu earned both his undergraduate and medical degrees from Brown University in Providence, Rhode Island. He completed his medical internship at the Hospital of St. Raphael at Yale University in New Haven, Connecticut, where he was awarded medical intern of the year in 1996. After his residency at Weill Cornell Medical Center in New York, with Fred Plum, MD, and Jerome Posner, MD, Dr. Hsu completed his fellowship training in neuro-oncology at The University of Texas MD Anderson Cancer Center.

Dr. Hsu was on the faculty at MD Anderson, where he served as assistant professor of neuro-oncology and neurology residency program director. He is a charter member of the Brain Tumor Network and has volunteered for several years for Run for the Rose, serving as the medical director from 2005 to 2007.

Dr. Hsu has presented research at several national conferences, and his work has been published in numerous journals and textbooks. His most recent research has focused on novel therapies for recurrent primary CNS lymphoma, recurrent glioblastoma multiforme and intralumbar injections for cancer therapy, and he has several patents granted and pending for his treatments.

Dr. Hsu’s expertise includes treatment of the following:

  • Cancer neurology
  • Chemotherapy neurotoxicity
  • Leptomeningeal metastases
  • Meningeal malignancies
  • Recurrent glioblastoma multiforme

Board Certifications

American Board of Psychiatry and Neurology

For Patients

If you are interested in learning more about Dr. Hsu’s clinical practice, please click below.

Sigmund H. Hsu, MD


Request Appointment »

Education

Graduate School
Brown University, Providence, Rhode Island
Internship
Hospital of St. Raphael, Yale University, New Haven, Connecticut
Residency
Columbia-Presbyterian New York Hospital, New York, New York (Neurology)
Fellowship
The University of Texas MD Anderson Cancer Center, Houston, Texas (Neuro-Oncology)

Publications

Articles in Peer-Reviewed Journals

  • Rosenthal JA, Hsu SH, Schneider D, Gentile LN, Messier NJ, Vaslet CA, Hawrot E Functional Expression and Site-directed Mutagenesis of a synthetic gene for alpha-bungarotoxin. Journal of Biological Chemistry 269:11178-11185, 1994
  • Puduvalli VK, Giglio P, Groves MD, Hess KR, Gilbert MR, Mahankali S, Jackson EF, Levin VA, Conrad CA, Hsu SH, Colman H, de Groot JF, Ritterhouse MG, Ictech SE, Yung WK A Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme Neuro-oncol 2008 10: 216-222
  • Groves MD, Glantz MJ, Chamberlain MC, Baumgartner KE, Conrad CA, Hsu SH, Wefel JS, Gilbert MR, Ictech S, Hunter KU, Forman AD, Puduvalli VK, Colman H, Hess KR, Yung WKA A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies Neuro-oncol, April 2008; 10: 208-215
  • Walbert T, Gilbert MR, Groves MD, Puduvalli VK, Alfred Yung WK, Conrad CA, Bobustuc GC, Colman H, Hsu SH, Nebiyou Bekele B, Qiao W, Levin VA. Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma. J Neurooncol. 2011 Apr;102(2):273-80. e-Pub 7/2010. PMID: 20652724.

Abstracts

  • Groves MD, Conrad C, Chamberlain M, Hsu S, Gilbert M, Forman A, Levin VA, Puduvalli V, Colman H, Yung WKA. A Phase II Study of Intrathecal Topotecan in Patients with Meningeal Malignancies. Society for Neuro-Oncology Eighth Annual Meeting, Keystone, CO, Abstract #TA-14, November 13-16, 2003
  • Gilbert M, Hess K, Liu V, Groves M, Puduvalli V, Levin V, Conrad C, Colman H, Hsu S, Sugrue M, Yung, WKA. A phase II study of temozolomide (TMZ) and the farnesyltransferase inhibitor (FTI) lonafarnib (Sarazartm, SCH66336) in recurrent glioblastoma. Society for Neuro-Oncology (combined meeting with the 6th Annual of the European Association of Neuro-Oncology/2nd Quadrennial Meeting of the World Federation of Neuro-Oncology), Edinburgh, UK, May 1-8, 2005. Neuro-Oncology 7(3):472, May 2005
  • Groves MD, Puduvalli V, Gilbert MR, Conrad CA, Hsu S, Colman H, Hess K, Levin VA, Yung WKA. A phase II study of temozolomide plus pegylated interferon alfa-2b for recurrent anaplastic glioma and glioblastoma multiforme. Abstract 1519, 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 13-17, 2005. J of Clinical Oncology 23(16S):1519, 2005
  • Puduvalli VK, Giglio P, Groves MD, Hess K, Jackson E, Mahankali S, Gilbert MR, Levin VA, Conrad CA, Hsu S, Colman H, Subramaniam H, Hunter G, WKA Yung. Phase II trial of Thalidomide in combination with Irinotecan in adults with recurrent glioblastomas. Abstract 1524, 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 13-17, 2005. J of Clinical Oncology 23(16S):1524, 2005
  • Wong FC, Groves M, Hsu S, Conrad CA, Kumar A, Fonnegra A, Wang Y, Pappadopoulus N, Sparks RB, Podoloff DA. Safety and radiation dosimetry profiles of intrathecal I-131 sodium iodide (Nal) in patients with leptomeningeal metastasis (LM). 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 13-17, 2005. J of Clinical Oncology 23(16S):3107, 2005
  • Wong F, Groves M, Papadopoulos N, Kim S, Conrad C, Meyers C, Hsu S, Kumar A, Tummala S, Kim E. Toxicity and efficacy profiles of intrathecal injection of I-131 Nal via intraventricular (Ivent) or intralumbar (Ilumb) route for leptomeningeal metastases (LM) therapy. 42nd Annual Meeting of the American Society of Clinical Oncology (ASCO), Atlanta, GA, June 2-6, 2006. J of Clinical Oncology 24(18S):1549, 2006
  • Gilbert MR, Gaupp P, Liu V, Conrad C, Colman H, Groves M, Puduvalli V, Levin V, Hsu S, Horowitz J, Yung W. A phase I study of temozolomide (TMZ) and the farnesyltransferase inhibitor (FTI), Ionafarnib (Sarazar, SCH66336) in recurrent glioblastoma. 42nd Annual Meeting of the American Society of Clinical Oncology (ASCO), Atlanta, GA, June 2-6, 2006. J of Clinical Oncology 24(18S):1556, 2006
  • Puduvalli VK, Giglio P, Groves MD, Hess KR, Gilbert R, Mahankali S, Hsu S, Colman H, Conrad C, Levin VA, Yung WKA. Phase II study of the combination of thalidomide and irinotecan in patients with recurrent anaplastic gliomas not on enzyme inducing anticonvulsants. 42nd Annual Meeting of the American Society of Clinical Oncology (ASCO), Atlanta, GA, June 2-6, 2006. J of Clinical Oncology 24(18S):1564, 2006
  • Wong FC, Groves M, Conrad D, Hsu S, Papadopulus N, Meyers C, Kim S, Fonnegra A, Podoloff DA and Kim EE. A Phase I Study of Intraventricular Injection of I-131 Sodium Iodide in Patients with Leptomeningeal Metastasis (LM). Neurology, Supplement 66 (2): A338, 2006
  • Wong FC, Groves M, Papadopulos N, Conrad C, Meyers C, Fonnegra A, Puduvali V, Hsu S and Kim EE. A Phase I Study using I-131 Nal to Treat Leptomeningeal Metastis via Lumbar Puncture, J Nuc Med 47( Supp 1): p 80P, 2006
  • Wong FC, Groves M, Papadopulos N, Conrad C, Meyers C, Kim,S, Puduvali V, Hsu S and Kim EE. Toxicity and efficacy profiles of intrathecal injection of I-131 NaI via intraventricular (IVent) or intralumbar (Ilumb) route for leptomeningeal metastases (LM) therapy. J Clin. Oncol., V24, No 18S, Part I of II, pp 70s, 2006
  • Gilbert MR, Gaupp P, Liu V, Conrad C, Colman H, Groves M, Puduvalli V, Levin V, Hsu S, Horowitz J, Yung W. A phase I study of temozolomide (TMZ) and the farnesyltransferase inhibitor (FTI), Ionafarnib (Sarazar, SCH66336) in recurrent glioblastoma. 42nd Annual Meeting of the American Society of Clinical Oncology (ASCO), Atlanta, GA, June 2-6, 2006. J of Clinical Oncology 24(18S):1556, 2006
  • Puduvalli VK, Giglio P, Groves MD, Hess KR, Gilbert R, Mahankali S, Hsu S, Colman H, Conrad C, Levin VA, Yung WKA. Phase II study of the combination of thalidomide and irinotecan in patients with recurrent anaplastic gliomas not on enzyme inducing anticonvulsants. 42nd Annual Meeting of the American Society of Clinical Oncology (ASCO), Atlanta, GA, June 2-6, 2006. J of Clinical Oncology 24(18S):1564, 2006
  • Conrad C, Madden T, Ji Y, Hsu S, Lang F, Priebe W. 2-Deoxy-D-Glucose, A novel drug to treat brain tumors. Southwest Regional Meeting of the American Chemical Society, Houston, Texas, October 19, 2006.

Book Chapters

  • Hsu S. Glial Tumors. In: Saunders Manual of Neurologic Practice, by Evans, R. (editor), Elsevier Science, New York, NY, 2003
  • Hsu S. CNS Tumors. In: Color-Matrix Cancer Staging and Chemotherapy Handbook, Lin, E. and Karp, D. (editor). UT M. D. Anderson Cancer Center, Division of Cancer Medicine, Houston TX, pp. 79-81, 2004
  • Hsu S, Yung WKA. Chemotherapy for brain metastases. In: Intracranial Metastases Current Management Strategies, Raymond Sawaya (editor), Futura/Blackwell Publishing, Malden, MA, pp. 183-195, 2004
  • Hsu S, Yung WKA. Tumors of the Central Nervous System. In: The M.D. Anderson Manual of Medical Oncology, by Kantarjian, H., Wolff, R. and Koller, C. (editors), McGraw-Hill Professional, New York, NY, pp. 787-817, 2006
  • Shonka N, Hsu S, Yung WKA. Tumors of the Central Nervous System. In: The M.D. Anderson Manual of Medical Oncology, by Kantarjian, H., Wolff, R. and Koller, C. (editors), 2nd Ed. McGraw-Hill Professional, New York, NY, pp. 1005-1038, 2011